BITX (formerly IRX) is a clinical-stage bioresearch company developing IRX-2, an important new immunotherapy candidate for cancer.
Total raised: $44.1M
Investors 1
| Date | Name | Website |
| - | Disruptive... | disruptive... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 20.01.2015 | - | $31.6M | - | medcitynew... |
| 24.05.2007 | - | $12.5M | - | venturebea... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 20.01.2015 | IRX Therap... | The company’s therapy ups the ... | - | - | medcitynew... |
| 05.06.2012 | Cancer imm... | At least 40 additional unique ... | - | - | medcitynew... |
| 24.05.2007 | IRX Therap... | New York’s IRX Therapeutics, a... | - | - | venturebea... |
| - | Cancer imm... | A company developing products ... | - | - | medcitynew... |
| - | IRX Therap... | New York biotech IRX Therapeut... | - | - | medcitynew... |